Is There Still a Role for Aprotinin in Cardiac Surgery?

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Safety

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00002018-200730090-00001PMID 17722966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

  2007cited by this paper
• Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.

  2007cited by this paper
• The risk associated with aprotinin in cardiac surgery.

  2006cited by this paper
• A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery.

  2006cited by this paper
• Influence of Cardiopulmonary Bypass on the State of Cognitive Functions in Patients with Ischemic Heart Disease

  2006cited by this paper
• A propensity score case‐control comparison of aprotinin and tranexamic acid in high‐transfusion‐risk cardiac surgery

  2006cited by this paper
• Inflammatory response and platelet activation after off-pump coronary artery bypass surgery

  2006cited by this paper
• Aprotinin improves cerebral protection: evidence from a survival porcine model.

  2006cited by this paper
• Observational studies of drug safety--aprotinin and the absence of transparency.

  2006cited by this paper
• Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass.

  2006cited by this paper
• Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.

  2006cited by this paper
• Indices of Apoptosis Activation After Blood Cardioplegia and Cardiopulmonary Bypass

  2006cited by this paper
• Use of P300 Cognitive Evoked Potentials in the Diagnosis of Impairments of Higher Mental Functions after Cardiac Surgery in Conditions of Cardiopulmonary Bypass

  2006cited by this paper
• Aprotinin to improve cerebral outcome after hypothermic circulatory arrest: a study in a surviving porcine model.

  2006cited by this paper
• Full-Dose Aprotinin Use in Coronary Artery Bypass Graft Surgery: An Analysis of Perioperative Pharmacotherapy and Patient Outcomes

  2006cited by this paper
• Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1.

  2006cited by this paper
• Aprotinin Attenuates the Elevation of Pulmonary Vascular Resistance After Cardiopulmonary Bypass

  2006cited by this paper
• Comparison of Serum Beta 2-Microglobulin and 24 hour Urinary Creatinine Clearance as a Prognostic Factor in Multiple Myeloma

  2006cited by this paper
• Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage.

  2005cited by this paper
• Kidney‐specific proteins in patients receiving aprotinin at high‐ and low‐dose regimens during coronary artery bypass graft with cardiopulmonary bypass

  2005cited by this paper
• Comparison of two strategies for the management of antiplatelet therapy during urgent surgery.

  2005cited by this paper
• Aprotinin Decreases Ischemic Damage During Coronary Revascularization

  2005cited by this paper
• Aprotinin Preserves Cellular Junctions and Reduces Myocardial Edema After Regional Ischemia and Cardioplegic Arrest

  2005cited by this paper
• Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting.

  2005cited by this paper
• Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial

  2005cited by this paper
• Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter.

  2005cited by this paper
• Aprotinin inhibits protease-dependent platelet aggregation and thrombosis.

  2005cited by this paper
• Protective effect of aprotinin against lung damage in patients undergoing CABG surgery

  2005cited by this paper
• Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?

  2005cited by this paper
• Serine Antiproteinase Administration Preserves Innate Superoxide Dismutase Levels After Acid Aspiration and Hyperoxia but Does Not Decrease Lung Injury

  2005cited by this paper
• Effects of aprotinin on endothelium-dependent relaxation of large coronary arteries.

  2005cited by this paper
• Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials

  2005cited by this paper
• Transfusion of Blood Products Affects Outcome in Cardiac Surgery

  2004cited by this paper
• Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence.

  2004cited by this paper
• The independent association of massive blood loss with mortality in cardiac surgery

  2004cited by this paper
• Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials.

  2004cited by this paper
• Induction and detection of disturbed homeostasis in cardiopulmonary bypass

  2004cited by this paper
• Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes

  2004cited by this paper
• Perioperative systemic haemostatic agents.

  2004cited by this paper
• The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery.

  2004cited by this paper
• The effect of aprotinin on hypoxia-reoxygenation-induced changes in neutrophil and endothelial function

  2004cited by this paper
• Does Off‐Pump Revascularization Reduce Coronary Endothelial Dysfunction?

  2004cited by this paper
• Aprotinin

  2004cited by this paper
• Aprotinin: a pharmacologic overview.

  2004cited by this paper
• Clinical Inhibition of the Seven-Transmembrane Thrombin Receptor (PAR1) by Intravenous Aprotinin During Cardiothoracic Surgery

  2004cited by this paper
• Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest.

  2004cited by this paper
• Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: A pilot randomized controlled study

  2004cited by this paper
• Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits).

  2004cited by this paper
• A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting.

  2003cited by this paper
• The systemic inflammatory response to cardiopulmonary bypass.

  2003cited by this paper
• Aprotinin and preservation of myocardial function after ischemia-reperfusion injury.

  2003cited by this paper
• Vasoplegic syndrome after off-pump coronary artery bypass surgery.

  2003cited by this paper
• Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1)

  2003cited by this paper
• Aprotinin restores the adhesive capacity of dysfunctional platelets.

  2003cited by this paper
• The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia

  2003cited by this paper
• Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress.

  2003cited by this paper
• Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion.

  2003cited by this paper
• The effect of clopidogrel incombination with aspirin whengiven before coronary artery bypass grafting

  2002cited by this paper
• Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery.

  2002cited by this paper
• Intraoperative treatment strategy to reduce the incidence of postcardiopulmonary bypass atrial fibrillation

  2002cited by this paper
• The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting.

  2002cited by this paper
• Aprotinin counteracts heparin-induced inhibition of platelet contractile force.

  2002cited by this paper
• Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells.

  2001cited by this paper
• New antiinflammatory and platelet-preserving effects of aprotinin.

  2001cited by this paper
• Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion.

  2001cited by this paper
• Aprotinin, Blood Loss, and Renal Dysfunction in Deep Hypothermic Circulatory Arrest

  2001cited by this paper
• Aprotinin and the systemic inflammatory response after cardiopulmonary bypass.

  2001cited by this paper
• The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1.

  2000cited by this paper
• Comparison of Blood-conservation Strategies in Cardiac Surgery Patients at High Risk for Bleeding

  2000cited by this paper
• CARDIOPULMONARY SUPPORT AND PHYSIOLOGY AN ANTI-INFLAMMATORY PROPERTY OF APROTININ DETECTED AT THE LEVEL OF LEUKOCYTE EXTRAVASATION

  2000cited by this paper
• Aprotinin administration in the pericardial cavity does not prevent platelet activation.

  2000cited by this paper
• Transfusion medicine. First of two parts--blood transfusion.

  1999cited by this paper
• Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.

  1998cited by this paper
• The platelet thrombin receptor and postoperative bleeding.

  1998cited by this paper
• Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?

  1996cited by this paper
• Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations.

  1996cited by this paper
• Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial.

  1996cited by this paper
• Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens.

  1996cited by this paper
• Vascular smooth muscle relaxation by alpha-adrenoceptor blocking action of dobutamine in isolated rabbit aorta.

  1996cited by this paper
• A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting.

  1995cited by this paper
• Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.

  1995cited by this paper
• Aprotinin in elective primary bypass surgery. Graft patency and clinical efficacy.

  1995cited by this paper
• Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting.

  1995cited by this paper
• Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage.

  1995cited by this paper
• Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans.

  1995cited by this paper
• Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study.

  1994cited by this paper
• Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization.

  1994cited by this paper
• Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood.

  1994cited by this paper
• Cardioplegia and vascular injury

  1994cited by this paper
• Cardioplegia and vascular injury. Dissociation of the effects of ischemia from those of the cardioplegic solution.

  1994cited by this paper
• Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom.

  1993cited by this paper
• Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.

  1993cited by this paper
• Expression Cloning and Characterization of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation

  1992cited by this paper
• Characterization of a functional thrombin receptor. Issues and opportunities.

  1992cited by this paper
• Problems with using observational databases to compare treatments.

  1991cited by this paper
• Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.

  1990cited by this paper
• Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol).

  1989cited by this paper
• Effect of aprotinin on need for blood transfusion after repeat open-heart surgery.

  1987cited by this paper
• Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs.

  1983cited by this paper

• Effect of Aprotinin on Liver Injury after Transplantation of Extended Criteria Donor Grafts in Humans: A Retrospective Propensity Score Matched Cohort Analysis

  2020cites this paper
• The risks associated with aprotinin use: a retrospective study of cardiac cases in Nova Scotia

  2012cites this paper
• The Effect of Ulinastatin on Postoperative Blood Loss in Patients Undergoing Open Heart Surgery with Cardiopulmonary Bypass

  2011cites this paper
• Application of remote ischaemic preconditioning to human coronary artery bypass surgery

  2010cites this paper
• Fatal intraoperative anaphylaxis after aprotinin administration.

  2008cites this paper
• The effect of aprotinin on outcome after coronary-artery bypass grafting.

  2008cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper